Compare ADMA Biologics Inc (ADMA) vs H2O America (HTO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs H2O America — how do they compare? ADMA Biologics Inc trades at $9.24 (market cap $2.13B), while H2O America trades at $61.63 (market cap $2.58B). The key difference: H2O America is the larger of the two by market cap, and H2O America pays a 2.85% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | HTO | |
|---|---|---|
Market Cap | $2.13B | $2.58B |
Sector | Health | Technology |
52-Week High | $20.38 | $62.42 |
52-Week Low | $7.60 | $44.44 |
Enterprise Value | $2.20B | $4.31B |
Dividend Yield | — | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
HTO trades at $61.21, down 1.94% on the day, with a bullish technical outlook supported by moving averages and a consensus price target of $61.33. The company reported Q1 2026 EPS of $0.50, beating expectations, and maintains strong fundamentals with a 12.87% net income margin. Recent news highlights executive appointments and institutional investments, reinforcing positive sentiment.
The stock presents a balanced opportunity with steady earnings growth and a reliable dividend, but faces risks from high RSI levels indicating overbought conditions and substantial capital expenditures. Analyst consensus is strongly bullish with 80% buy ratings, though investors should monitor execution of growth initiatives and sector-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →
